- Several European countries have paused the roll-out of the AstraZeneca/Oxford vaccine on concerns over elevated levels of blood clotting
- 11m AstraZeneca/Oxford vaccine doses have been administered in the UK, with only 40 embolism cases recorded
An investigation into the cause of blood clots has led several of Europe’s medicines regulators to pause the roll-out of the AstraZeneca/Oxford vaccine after cases came to light in Norway, Ireland and Germany. Regulators will meet to discuss the significance of these cases in the context of a programme that has seen 17m Oxford jabs administered so far, 11m of those in the UK alone.
The questions for pharmaceutical market watchers are whether there is any real scientific basis for worries about the vaccine, whether it is just another example of creeping ‘vaccine nationalism’ and whether it will have any conceivable commercial impact on AstraZeneca?